ABG
AXSM icon

Ally Bridge Group’s Axsome Therapeutics AXSM Stock Holding History

Ally Bridge Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$5.83M – 25
2025
Q1 		$5.83M Buy
+50,000
New +$5.7M 5.26% 8

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ally Bridge Group's AXSM Position: Q2 2025 in Review

Ally Bridge Group sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 72,113 shares — an estimated $8.41M sold.

Ally Bridge Group first reported a position in AXSM in Q3 2023 and held it in 4 quarters. The position peaked at $8.41M in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Ally Bridge Group reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ally Bridge Group sold 72,113 Axsome Therapeutics shares in Q2 2025, an estimated $8.41M.
  • Ally Bridge Group first reported a position in Axsome Therapeutics in Q3 2023 and held it in 4 quarters.
  • Ally Bridge Group's Axsome Therapeutics position peaked at $8.41M in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.